DOI QR코드

DOI QR Code

Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand

  • Potikul, Chalermrat (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) ;
  • Tangjitgamol, Siriwan (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) ;
  • Khunnarong, Jakkapan (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) ;
  • Srijaipracharoen, Sunamchok (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) ;
  • Thavaramara, Thaovalai (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University) ;
  • Pataradool, Kamol (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University)
  • Published : 2016.06.01

Abstract

Background: Uterine sarcoma is a group of rare gynecologic tumors with various natures, and different lines of treatment. Most have a poor treatment outcome. This study targeted clinical characteristics, treatment, overall survival (OS), progression-free survival (PFS), and prognostic factors in uterine sarcoma patients in one tertiary center for cancer care. Materials and Methods: Uterine sarcoma patients who were treated at the Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital between January 1994 and December 2014 were identified. Clinico-pathological data were analyzed. Prognostic outcomes were examined by Kaplan-Meier curves and Cox regression analysis. Results: We identified 46 uterine sarcoma patients: 25 carcinosarcoma (CS) (54.3%), 15 leiomyosarcoma (LMS) (32.6%), and 6 undifferentiated uterine sarcoma (UUS) (13.1%) cases. Mean age was $54.0{\pm}11.9years$ (range 25-82 years). Abnormal uterine bleeding was the most common presenting symptom (63.0%). Among 33 patients (71.7%) who had pre-operative tissue collected, diagnosis of malignancy was correct in 29 (87.9%). All patients received primary surgery and retroperitoneal lymph nodes were resected in 34 (73.9%). After surgery, 5 (10.9%) had gross residual tumors. Stage I disease was most commonly found (56.5%). Adjuvant treatment was given to 27 (58.7%), most commonly chemotherapy. After a median follow-up of 16.0 months (range 0.8-187.4 months), recurrence was encountered in 22 patients (47.8%). Median time to recurrence was 5.8 months (range1.0-105.5 months). Distant metastasis was more common than local or locoregional failure. The 2-year PFS was 45.2% (95% confidence interval [CI], 30.6%-59.7%) and the 2-year OS was 48.3% (95% CI, 33.3%-60.7%). Multivariable analyses found residual disease after surgery as a significant factor only for PFS. Conclusions: Uterine sarcoma is a rare tumor entity. Even with multimodalities of treatment, the prognosis is still poor. Successful cytoreductive surgery is a key factor for a good survival outcome.

References

  1. Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD (2008). The utilty of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol, 110, 43-8. https://doi.org/10.1016/j.ygyno.2008.02.026
  2. Benito V, Lubrano A, Arencibia O, et al (2009). Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. Int J Gynaecol Obstet, 1079, 44-9.
  3. Brooks SE, Zhan M, Cote T, Baquet CR (2004). Surveillance, epidemiology and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol, 93, 204-8. https://doi.org/10.1016/j.ygyno.2003.12.029
  4. Cantrell LA, Blank SV, Duska LR (2015). Uterine carcinosarcoma: A review of the literature. Gynecol Oncol.
  5. Durnali A, Tokluoglu S, Ozdemir N, et al (2012). Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey. Asian Pac J Cancer Prev, 13, 1935-41. https://doi.org/10.7314/APJCP.2012.13.5.1935
  6. Gao Y, Meng H, Zhang Y, Jiao T, Hui N (2014). Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China,1988-2007. Int J Clin Exp Pathol, 7, 1616-24.
  7. Ghaemmaghami F, Zarchi MK, Gilani MM, et al (2008). Uterine sarcoma : clinicopathological characteristics, treatment and outcomes in Iran. Asian Pac J Cancer Prev, 9, 421-6.
  8. Hensley ML, Ishill N, Soslow R, et al (2009). Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol, 112, 563-7. https://doi.org/10.1016/j.ygyno.2008.11.027
  9. Homesley HD, Filiaci V, Markman M, et al (2007). Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 526-31. https://doi.org/10.1200/JCO.2006.06.4907
  10. Kapp DS, Shin JY, Chan JK (2008). Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer, 112, 820-30. https://doi.org/10.1002/cncr.23245
  11. Kelly KL, Craighead PS (2005). Characteristics and management of uterine sarcoma patients treated at Tom Baker Cancer Centre. Int J Gynecol Cancer, 15, 132-39. https://doi.org/10.1111/j.1048-891x.2005.15014.x
  12. Koivisto-Korander R, Butzow R, Koivisto A, Leminen A (2008). Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990–2001. Gynecol Oncol, 111, 74–81. https://doi.org/10.1016/j.ygyno.2008.06.002
  13. Kushner DM, Webster KD, Belinson JL, et al (2000). Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynocol Oncol, 78, 221-7. https://doi.org/10.1006/gyno.2000.5875
  14. Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS (2003). Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol, 91, 209-12. https://doi.org/10.1016/S0090-8258(03)00478-5
  15. Livi L, Paiar F, Shah N, et al (2003). Uterine sarcoma: Twentyseven years of experience. Int J Radiation Oncol Biol Phys, 57, 1366-73. https://doi.org/10.1016/S0360-3016(03)00750-8
  16. Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol, 25, 2755-63. https://doi.org/10.1200/JCO.2006.10.4117
  17. McCluggage WG (2002). Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer, 12, 687-90. https://doi.org/10.1046/j.1525-1438.2002.01151.x
  18. Muss HB, Bundy B, Disaia PJ, et al (1985). Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group). Cancer, 55, 1648-53. https://doi.org/10.1002/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7
  19. O'Cearbhail R, Hensley ML (2010). Optimal management of uterine leiomyosarcoma. Expert Rev. Anticancer Ther, 10, 153-69. https://doi.org/10.1586/era.09.187
  20. Oliva E, Carcangiu ML, Carinelli SG, et al (2014). Mesenchymal tumours. In "WHO classification of tumors of female reproductive organs", Kurman RJ. IARC Press, France 135-47.
  21. Park JY, Kim DY, Suh DS, et al (2008). Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007. J Cancer Res Clin Oncol, 134, 1277–87. https://doi.org/10.1007/s00432-008-0422-2
  22. Powell MA, Filiaci VL, Rose PG, et al (2010). Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic oncology Group Study. J Clin Oncol, 28, 2727-31. https://doi.org/10.1200/JCO.2009.26.8326
  23. Prat J (2009). FIGO staging for uterine sarcomas. Int J Gynaecol Obstet, 104, 177-8. https://doi.org/10.1016/j.ijgo.2008.12.008
  24. Rauh-Hain JA, del Carmen MG (2013). Endometrial stromal sarcoma: a systematic review. Obstet Gynecol, 122, 676-83. https://doi.org/10.1097/AOG.0b013e3182a189ac
  25. Reed NS, Mangioni C, Malmström H, et al (2008). Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer, 44, 808-18. https://doi.org/10.1016/j.ejca.2008.01.019
  26. Sutton G, Brunetto VL, Kilgore L, et al (2000). A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol, 79, 147-53. https://doi.org/10.1006/gyno.2000.6001
  27. Tangjitgamol S, Khunnarong J, Katanyoo K, et al (2015). Patterns of adjuvant therapy for endometrial cancer: Single institutional experience in Thailand. Int J Gynecol Cancer, 25, 665-72. https://doi.org/10.1097/IGC.0000000000000391
  28. Tangjitgamol S, Khunnarong J, Srijaipracharoen S (2014). Medical morbidities in endometrial cancer patients. Int J Gynecol Cancer, 24, 1623-7. https://doi.org/10.1097/IGC.0000000000000291
  29. Thigpen JT, Blessing JB, Beecham J, Homesley H, Yordan E (1991). Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcoma: A Gynecologic Oncology Group study. J Clin Oncol, 9, 1962-6. https://doi.org/10.1200/JCO.1991.9.11.1962
  30. Ulrich LG (2015). Benign leiomyoma or malignant sarcoma: The difficult differential diagnosis. Maturitas, 80, 235-6. https://doi.org/10.1016/j.maturitas.2014.12.021
  31. Wells M, Oliva E, Palacios J, Prat J (2012). Mixed epithelial and mesenchymal tumours. In "WHO classification of tumors of female reproductive organs", Kurman RJ. IARC Press, France 148-51.

Cited by

  1. Trends of uterine cancer incidence: a projection from the past to the future vol.30, pp.2, 2019, https://doi.org/10.3802/jgo.2019.30.e36